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Background: Colorectal cancer (CRC) is the second leading cause of death from cancer in the United States.
Colorectal cancers have a prolonged latency following initiation that may span decades providing ample time for
implementing a chemoprevention strategy that could block or reverse the progression to CRC. Cdk4 pathway
alterations have been linked to a number of cancers including CRC. In these experiments we focused on the Cdk4
pathway and its role in intestinal tumorigenesis as a possible target in chemoprevention strategies.
Methods: We evaluated the effect of Cdk4 blockade on the prevention of intestinal tumor formation by crossing
Cdk4−/− mice to Apc−/+ mice. In addition, we tested the effect of the dietary compound silibinin on the Cdk4
pathway in Apc−/+ mice and HT-29 colon cancer cells in culture.
Results: Cdk4−/− mice backcrossed to Apc−/+ mice reduced intestinal adenoma formation compared to Apc−/+
controls. Silibinin effectively targeted the Cdk4 pathway causing hypophosphorylation of the retinoblastoma
protein, inhibited cell growth, and induced apoptosis. As a result silibinin blocked the development of intestinal
adenomas by 52% in this genetic model (Apc−/+ mice) of early events in colorectal cancer formation. No toxic
abnormalities were detected in mice which received silibinin.
Conclusions: Modification of the Cdk4 pathway using a natural plant-derived compound such as silibinin may be a
useful chemopreventive strategy for colorectal carcinomas.
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Disruption of cell cycle regulation through alterations in
the Cdk4 pathway appears to play an important role in
the development of a variety of cancers including colo-
rectal cancer [1,2]. It is now clear that colorectal cancers
begin with intestinal epithelial cell clones that lose the
function of the Apc pathway (gatekeeper function) [3,4].
Apc is part of the cellular Wnt signaling pathway and is
an upstream regulator of many components of the Cdk4
pathway [5,6]. Loss of Apc function acts to upregulate
c-Myc and cyclin D1 expression [7-9]. c-Myc is a direct
activator of Cdk4 as the Cdk4 gene has 4 conserved
c-Myc binding sites in its promoter [10]. Cdk4 is a key
regulator of the cell cycle, and when Cdk4 becomes active
by binding to cyclin D1, it allows cells to enter the G1* Correspondence: bkarim@jhmi.edu
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reproduction in any medium, provided the orphase of the cell cycle and progress towards the S phase
by phosphorylating retinoblastoma (Rb) protein. This
leads to release of E2F transcription factors that function
to activate the transcription of genes involved in DNA
synthesis [8,11]. Therefore, Apc mutations, acting in part
through the activation of the Cdk4 pathway, play a critical
role early in intestinal tumorigenesis [12,13].
Many studies suggest the utility of natural compounds
as chemopreventive agents against CRC [14,15]. Some
compounds derived from natural sources have been
shown to inhibit the cell cycle at points regulated by
various components of the Cdk4 pathway, blocking pro-
liferation of cancer cells [16-18]. For example, milk this-
tle, also referred to as St. Mary's thistle, lady thistle, or
holy thistle, contains polyphenolic flavanoid antioxidant
compounds composed mainly of silibinin. For several de-
cades, silymarin, a compound derived from milk thistle
and related to silibinin, has been used empirically around
the world for the treatment of liver cirrhosis [19]. Recenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in vitro and in vivo and causes G1 arrest of the cell cycle
(regulated by the Cdk4 pathway) [17].
In this study, we examined the Cdk4 pathway and its
blockade in the context of Apc mutation to determine
the potential for targeting this pathway in a chemopre-
ventive strategy for colorectal cancer. In these experi-
ments, we compared the effects of Cdk4 pathway
blockade on the number and size of adenomas in the
Apc−/+ Cdk+/+ with Apc−/+ Cdk4−/− mice to characterize
the role of the Cdk4 pathway in tumor development
in vivo. Furthermore, we found silibinin effectively op-
poses Cdk4 pathway activation at several points and
administration as a chemopreventive agent resulted in
reduced cell proliferation, increased apoptosis, and re-
duced adenoma development in Apc−/+ mice.
Methods
Animal model
C57BL/6-Apctm1.Δ716 mice were generously provided by
Drs. Vogelstein and Kinzler [20]. Apc heterozygote (Apc
−/+) offspring were genotyped at three weeks of age. A
Cdk4-null mutation, Cdk4tm1Kiyo (Cdk4−/−) mice were
provided by Kiyokawa [21]. To generate double mutant
Apc−/+ Cdk4−/− mice, Apc−/+ were crossed with Cdk4−/+
mice. The resulting Apc−/+ Cdk4−/+ were crossed to Apc
+/+ Cdk4−/+ to generate Apc−/+ Cdk4−/− mice. All ani-
mals were maintained on a mixed 129/C57BL/6 back-
ground. Pups were genotyped by PCR. For the Apc gene,
the primers used were A, 5- GACTGCAGATCTC
TCCAAG −3; B, 5-CTAAAGCGCATGCTCCAGACT-3;
and C, 5-AAGAAGAGCTGGGCAATACCGTA-3. For
Cdk4 −/− genotyping, the following primers were used:
A, 5- ATATTGCTGAAGAGCTTGGCGG-3; B, 5-
CGGAAGGCAGAGATTCGCTTAT-3; and C, 5-
CCAGCCTGAAGCTAAGAGTAGCTGT-3. Mice were
fed AIN-76A diet and water ad libitum, were exposed to
12-hour-light/12-hour-dark cycles, and were maintained
under specific pathogen free conditions including pin-
worms, Helicobacter spp, and Citrobacter rodentium.
The wild-type Apc allele generated a 1171-bp product,
and the heterozygous allele formed one wild type allele
and one knockout allele, below 1000-bp in size. The
wild-type Cdk4 allele generated a 195-bp product, and
the mutant allele formed a 315-bp product. We used
age- and sex- matched littermate controls. All experi-
ments on animals were approved in accordance with the
Institutional Animal Care and Use Committee at The
Johns Hopkins University.
Analysis of intestinal adenoma
At the age of four months, Apc−/+ Cdk4−/− and Apc−/+
Cdk4+/+ female mice were euthanized by cervical dis-
location. The intestines were excised, opened, laid flat,washed in phosphate buffered saline, and stained with
methylene blue then de-stained with 20% alcohol five to
six times to desired color and contrast. The numbers of
adenomas were counted using a dissecting microscope
in both small and large intestine, blinded as to group.
Questionable lesions were examined histologically to
confirm them as adenomas. Also, the number of aden-
omas was classified according to their size (< 1 mm,
1–2 mm, 2–3 mm, > 3 mm). The intestines were rolled,
embedded, and sectioned for microscopic examination.
Immunohistochemistry
The adult Apc−/+ mice were euthanized by cervical dis-
location. The intestines were opened longitudinally,
washed in PBS, and fixed in 10% buffered formalin.
Then the intestines were rolled and submitted for em-
bedding. Five-μm-thick sections were prepared and sec-
tions were deparaffinized in xylene, and rehydrated
through graded alcohols. Slides were transferred to a jar
containing unmasking solution (Vector Laboratories,
H-3300), boiled for 10 minutes, and left in the same
solution at room temperature for 20 minutes. Endogen-
ous peroxidase was quenched with hydrogen peroxide
for 10 min. All slides were then incubated with 10%
blocking serum (Vector Laboratories), from the animal
species from which the secondary antibody was made, in
PBS for 30 min at room temperature to saturate
nonspecific protein binding sites. The slides were incu-
bated with primary antibody (Cdk4, pRb, and cyclin D1)
diluted 1:100 for 60 minutes at room temperature (Cell
Signaling Technology, Cdk4: 2906, pRb: 9308, cyclin D1:
2926). After three washes with 0.1% Tween 20 in PBS,
sections were incubated for 30 minutes with biotinylated
secondary antibody IgG (Vector laboratories) diluted
1:500 in blocking solution. After three washes, sections
were incubated for 30 min with ABC reagent. The slides
were then washed for 5 minutes three times. The final
reaction was produced by immersing the sections in a
peroxidase substrate with nickel enhancer (Vector Labora-
tories, SK-4100) at room temperature. Controls for immu-
nostaining included incubations with matched rabbit
immunoglobulins. Photographs of histological sections
were taken using a Nikon digital camera (DXTM1200).
For both proliferation and apoptosis, silibinin and ve-
hicle treated Apc−/+ mice were euthanized at the age of
four months and immunohistochemistry was performed
as described above. For proliferation assays we used
Ki67 primary antibody (Lab Vision Corp, RM-9106-S).
For apoptosis: after rehydration, slides were transferred
to coplin jars containing Proteinase K (Dako, S3020) at
37°C for 15 min. After washing, TUNEL reagent (in situ
cell death detection kit fluorescein; Roche #1684795)
was added and slides were placed in a humid chamber
for 60 minutes at 37°C in the dark. Slides were washed
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three times with distilled water. Cover slips were mounted
with crystal mount (Biomeda, M02). The number of
TUNEL and Ki67 positive cells were counted per high
power field (400×) per 4 crypts in normal regions of the
mucosa and within the adenomas. The quantification was
scored, blinded to intervention (treatment/control).
Growth inhibition assay
HT-29 (2 × 10 4) cells were seeded into each well of a
96-well plate in 100 μL tissue culture DMEM medium
supplemented with 10% heat-inactivated fetal bovine
serum (FBS), and 2 mmol/L glutamine, at 37°C in a hu-
midified atmosphere containing 5% carbon dioxide and
95% air. After 24-hour incubation to allow cells to ad-
here, cells were treated with silibinin (Sigma Aldrich),
esculetin (Sigma Aldrich), curcumin (Sigma Aldrich), or
vitamin D analog (unpublished new analogue) at differ-
ent concentration (0.1, 1, 10, 100 μM). Cultures were
incubated for an additional 24 hours. Inhibition of pro-
liferation was determined by a reproducible colorimetric
assay. The key component is (3-{4,5-dimethylthiazol-2-
yl}-2,5-diphenyl tetrazolium bromide) or MTT using
medium or balanced salt solutions without phenol red
(Sigma, M-5655). This assay measures the bioreduction
by intracellular dehydrogenases of the tetrazolium com-
pound MTT. MTT was added to the culture wells, and
the mixture was incubated for 3 hours at 37°C. Then,
MTT was removed and MTT solubilization solution
(Sigma, M-8910) was added to the well. Absorbance was
measured at 570 nm using a microplate reader. Viability
was calculated from relative dye intensity of the mean
for duplicate samples and presented as percentages rela-
tive to vehicle samples.
In addition, after growing and treating cells with differ-
ent concentrations of silibinin for 24 hours as described
above, the cells were trypsinzed and neutralized by
medium, stained with 0.4% trypan blue solution to deter-
mine viability by dye exclusion and quantitated using a
hemocytometer. All assays were performed with four
replicates.
Detection of inhibition of proliferation by flow cytometry
To quantify silibinin inhibition of proliferation of HT-29
cells, Ki67 staining was used followed by flow cytometry.
HT-29 cells were plated in 25 mm dishes. At 50%
confluency, cells were treated with different concentra-
tions of silibinin (0, 0.1, 1, 10, and 100 μM). 1 × 106
cells were collected, fixed and permeabilized using the
protocol described for the BD Cytofix/Cytoperm Kit
(Becton Dickinson). Briefly, cells were resuspended in
100 μl of Cytofix/Cytoperm solution for 15 min at 4°C.
Cells were washed twice in 1 × Perm/Wash Buffer, and
resuspended in 100 μl of Perm/Wash Buffer. Then, 10 μlKi67 FITC-conjugated antibody (BD) was added to fixed
and permeabilized cells for 30 minutes in the dark at room
temperature. Cells were washed and resuspended in stain-
ing buffer (BD). Proliferation was analyzed by flow cytom-
etry (Facscalibur, Becton Dickinson). Experiments were
performed at least three times.Western blotting
HT-29 cells were treated with different concentrations
of silibinin, (0.1, 0.5, 1, 10, and 100 μM) or with vehicle
(DMSO) for 24 hours. To prepare whole cell extracts for
in vitro study, HT-29 cells treated with silibinin were
washed with TBS and suspended in lysis buffer
containing protease/phosphatase-inhibitor cocktail (Cell
Signaling Technology, 5872). After mixing for 30 minutes
at 4°C, the mixture was centrifuged for 10 minutes, and
supernatants were collected. For in vivo studies 0.2% of
silibinin and control diet were given to Apc−/+ mice for
five days. The purification of the mucosal lining of the
intestine was performed as described in reference [22]
with mild m odification. Briefly, after euthanizing the
animal, the small intestines were excised and a 5 cm
bowel segment from duodenum, jejunum, and ileum
were opened on ice and washed with ice cold TBS. All
three pieces were placed in a tube containing 0.14 M
NaCl containing 5 mM EDTA (pH 7.4). The tubes were
vortexed for 30 minutes at 4°C. Detached mucosal cells
from all pieces were collected by centrifugation at 800 g
for 30 seconds at 4°C and suspended in 10 ml of buffer
containing 12 mM Tris-HCl (pH7.4), 0.3 M mannitol,
10 mM KCl, 0.5 mM EDTA, and a protease/phosphat-
ase-inhibitor cocktail. The protein content from the in-
testinal mucosal cells and the supernatants from HT-29
cell line were determined using the Biorad protein assay
reagent with bovine serum albumin as a standard. Thir-
teen μg of protein were separated on 6–10% Novex Bis-
Tris Gel (Invitrogen) and transferred onto a nitrocellu-
lose membrane. Loading of equal protein amounts was
assessed by the Biorad assay. The rest of the procedure
followed according to the manufacturers protocol (Cell
Signaling Technology). Briefly nonspecific binding to the
membrane was blocked for 1 hour of incubation with
agitation at room temperature. Anti-pRb, anti-Rb, anti-
cyclin D1, anti-Cdk4 (1:1000), and anti-actin (1:400)
antibodies were added overnight at 4°C. All antibodies
were purchased from Cell Singling Technology, 9308,
9309, 2926, 2906, and 8456 respectively. The horseradish
peroxidase-conjugated goat anti-rabbit secondary anti-
body was incubated at 1:2000 for 1 hour at room
temperature. Following three washes with Tris-buffered
saline, the protein bands were visualized with LuminGLO
for 1 min at room temperature. The bands were visualized
on film (Kodak) exposed to the membrane to detect
Figure 1 Macroscopic dissection and microscopic views of the
adenomas. A: Numerous adenomas (arrow) of various sizes observed
within the intestine of an Apc−/+ mouse. B: Histomorphological
features of the small intestinal adenoma, H&E staining. C: Higher power
view of the adenoma.
Karim et al. BMC Cancer 2013, 13:157 Page 4 of 11
http://www.biomedcentral.com/1471-2407/13/157chemiluminescence signals. Experiments were repeated
three times.
Treatment protocol
At the age of 30 days, the Apc−/+ mice (groups of 11)
were fed either with 0.2% silibinin (w/w) in the diet
(AIN-93G, gamma irradiated ground meal diet) or pla-
cebo (diet alone) for three months. The diet was made
fresh every week and stored at −20°C in the dark to
minimize photo destruction of nutrients and silibinin.
Fresh diet was provided every three days at the time of
cage change. The weight of the mice was recorded twice a
week. At the age of 4 months, the mice were euthanized;
serum chemistry and hematology were evaluated by a
commercial laboratory (Antech Inc.). Adenomas were
counted as described previously at the age of four months.
Data analysis
Data are presented as the mean and standard error of mean
or as a percentage with standard deviation (GraphPad,
PRISM software, San Diego). The Mann-Whitney Test was
used to compare body weights, and P values were deter-
mined by using the Student two-tailed t test unless other-
wise indicated. Tumor data were analyzed using Chi square
(χ2) test and other differences using the Student’s t test. Dif-
ferences were considered statistically significant at p < 0.05.
Results
Figure 1 shows hematoxylin and eosin staining of the in-
testine and adenomas from mutant Apc−/+ mice. Histolog-
ically, adenomas were characterized by proliferation of
variably dysplastic epithelium, with minor differentiation
into mature goblet or absorptive cells [23]. Intestines from
Apc−/+ mice were analyzed by immunohistochemistry for
the expression and distribution of three central compo-
nents of the Cdk4 signaling pathway downstream of Apc
mutation, Cdk4, cyclin D1, and pRb. The results show that
all mice had nuclear staining for all three markers within
the nuclei from normal crypts as well as from adenomas
(Figure 2A, B, and C). There were differences in the inten-
sity of the staining in different mice in some instances for
the same marker. The pattern of Cdk4 and cyclin D1
staining was strongest in the crypts and adenomas and
almost absent from the villi. For pRb, there was stronger
staining in the crypts and adenomas with weak staining of
the villi. We conclude that indeed there is prominent ex-
pression of Cdk4 pathway components throughout aden-
oma epithelium.
To further define a potential role for Cdk4 blockade in
preventing intestinal tumor formation, we generated
double mutant mice, Apc−/+ Cdk4−/−, and compared
them to control Apc−/+ Cdk4+/+ mice. Adenomas were
counted manually as described in the materials and
methods section using a dissecting microscope. Doublemutant mice exhibited significantly reduced adenomas,
compared with Apc−/+ Cdk4+/+ mice along their entire
small and large intestine at 120 days of age. The lack of
Cdk4, reduced the sizes of all adenomas by 65%. The
number of microadenomas that were less than 1 mm in
diameter were significantly decreased in double mutant
mice, Apc−/+ Cdk4−/−, (Figure 3).
We next compared several potential candidate com-
pounds for their effectiveness as inhibitors of Cdk4 signal-
ing and cell proliferation in vitro. We found that among
esculetin, curcumin, a vitamin D analogue, and silibinin, all
inhibited the Cdk4 pathway at various doses. However,
silibinin possessed the best combination of efficacy in
inhibiting Cdk4 signaling and lack of toxicity in treated
cells at the effective dose. Esculetin, curcumin, and vitamin
D analogue treated cells exhibited detectable toxicity (re-
duced viability) at doses that displayed evidence of Cdk4
pathway inhibition and therefore were not studied further.
Figure 2 Immunohistochemical staining of Cdk4 (A), cyclin D1 (B), and pRb (C) in intestine. Left: Low power view (50×) showing normal
intestinal mucosa and adenoma. Right: higher magnification (200×) of the intestinal adenoma.
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viability was monitored over time in culture as a func-
tion of mitochondrial activity in living cells using the
MTT assay. The inhibition of proliferation for silibinin
treated cells was clearly dose dependent (Figure 4). A re-
duction of proliferation was statistically significant at
100 μM in cells treated with silibinin. A similar pattern
was noted when we counted viable HT-29 cells using
the trypan blue assay and a hemocytometer. In addition,
the Ki67 labeling index confirmed the effects of silibinin
on cell growth as measured by flow cytometry. The in-
hibition of expression of Ki67 in HT-29 cells was stron-
gest at 100 μM. While the expression of Ki67 in HT-29Figure 3 Distribution of adenomas by size in Apc−/+ Cdk4+/+ (white ba
intestine. The percent of control adenomas are indicated with SEM. The n
t test. (*p < 0.05 versus control. n = 15 animals/group).treated cells at 0.1 and 1 μM was almost similar to non-
treated cells.
To further evaluate Cdk4 pathway activity, we mea-
sured downstream phosphorylated Rb (pRb) and binding
partner cyclin D1 in whole cell lysates isolated from vi-
able HT-29 cells treated with different concentrations
(0.1, 0.5, 1, 10, and 100 μM) of silibinin. Proteins were
examined by Western blot using chemiluminescence for
detection. Results in Figure 5A show there is significant,
dose-dependent reduction in levels of phosphorylated
Rb and cyclin D1. This indicated that silibinin causes
hypophosphorylation of Rb protein and also reduces cel-
lular levels of cyclin D1.r) and in Apc−/+ Cdk4−/− mice (filled bar) in small (A) and large (B)
umber of adenomas were analyzed by the Chi square test and Student
Figure 4 Cell growth, viability, and Ki67 staining of the silibinin treated HT-29 cells. A: HT-29 cells were incubated with vehicle (DMSO)
and silibinin, at 0, 0.1, 1, 10, and100 μM and cells or events counted at 24 hours. Results shown are the average of triplicate determinations.
Results are expressed as the mean and normalized against their own control, vehicle. (Bar = SEM. * P < 0.05 versus control). B: Analysis of
proliferation in HT-29 treated cells by flow cytometry.
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silibinin had a similar effect on phosphorylation of Rb in
intestinal mucosal tissue. Western blot analysis was
performed on the protein extracted from the mucosa
from mice that were fed control diet or a diet containing
0.2% silibinin in the food. The phospho-specific pRb and
cyclin D1 bands were reduced significantly in animals
receiving silibinin (0.2%) for five days (Figure 5B). Rb
and Cdk4 protein levels were the same in silibinin-
treated and non-treated mice (Figure 5C).
To determine if silibinin was effective in preventing
adenomas, a known precursor to colorectal cancer, we
next performed a chemopreventive study using the Apc
mouse model. Our data show that a diet containing 0.2%
silibinin significantly reduced the number of large and
small intestinal adenomas (Figure 6). The total number
of adenomas decreased by 52% in silibinin treated mice
compared to those with vehicle only. The number of ad-
enomas that were less than 2 mm in diameter were sig-
nificantly decreased in silibinin treated animals. The
adenomas that were larger than 2 mm in diameter were
also reduced in silibinin treated animals; however, the
reduction did not reach significance. The body weight
gains, gross examination, and microscopic examination,
serum chemistry, and blood counts were within normallimits with no indications of toxic side effects at the dos-
age of silibinin that was used (data not shown).
Cell cycle activity in the intestinal epithelium in
silibinin treated and control Apc−/+ mice were compared
using immunohistochemistry for Ki67 (Figure 7). Nor-
mal crypt Ki67 staining was substantially reduced (33%)
in mice that were on silibinin comparing to the mice
that received control diet. The mean proliferation index
within the normal crypts in the mice that were on
silibinin was 61 but was 90 in the mice that received no
intervention, (p < 0.01 in t test). Also, there was strong
repression of Ki67 positive cells within the adenomas
from the mice that were on silibinin. In addition, the
mean proliferative index within the adenomas was 191
in the mice that were on silibinin but 330 in the mice re-
ceived control food, (P < 0.01 in t test) (Figure 7).
Apoptosis of intestinal epithelial cells was character-
ized in intestinal tissue histologically according to an
apoptotic index using the TUNEL assay. Apoptosis was
found in the crypts, epithelial cells on the small intes-
tinal villi, crypts, and intercrypt table of the colon. The
results demonstrated that the mice that were on silibinin
had significantly increased numbers of apoptotic cells
(average per field 3.1) in crypts in the normal mucosa
compared to the mucosa in mice that were on control
Figure 5 Western blot analysis of pRb, cyclin D1, Cdk4, and Rb. A: Analysis of cyclin D1 and pRb in total cell lysates from HT-29 cell line
treated with 0.1, 0.5, 1, 10, 100 μM of silibinin. B and C: Analysis of cyclin D1, pRb, Cdk4, and Rb of the mucosal cells lining the intestine after
silibinin administration for 5 days. The blots were re-probed using β-actin as a loading control.
Figure 6 Distribution of adenomas by size in Apc−/+ (white bar) and in Apc−/+ mice that received silibinin (filled bar) in small (A) and
large (B) intestine. The percent of control adenomas are indicated with SEM. The number of adenomas were analyzed by Chi square test and
Student t test. (*p < 0.05 compared with control. n = 11 animals/group).
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Figure 7 Silibinin affects Ki67 expression in Apc−/+ mice. Representative examples of immunohistochemical analysis of Ki67 in Apc−/+ control
(A) and silibinin treated mice (B). Quantification of Ki67 immunostaining within the adenomas (C) and within the crypts (D) in control (empty bar)
and silibinin treated mice area (filled bar). (*p < 0.01 compared with control, by t test. n = 4 animals/group).
Figure 8 Immunofluorescent detection of apoptotic cells in intestinal adenoma. Representative analysis of tunnel staining in Apc−/+ control
(A) and silibinin treated mice (B). Quantification of tunnel positive cells within the polyps (C) and within the crypts (D) in control (empty bar) and
silibinin treated mice area (filled bar). (*p < 0.01 compared with control, by t test. n = 4 animals/group).
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number of apoptotic cells was higher within adenomas
in the mice that were on silibinin (180) compared to the
mice that received no intervention (48) (Figure 8). These
differences between silibinin treated and control mice
that were seen in both the crypts in the unaffected mu-
cosa and in the adenomas were statistically significant,
(p value < 0.01).Figure 9 Schematic model of potential silibinin effects on the
Cdk4 pathway in controlling tumor formation. Blockade of Cdk4
pathway (cyclin D1, Cdk4 activity, and pRb) and inhibition of cell
cycle entry.Discussion
Mutation in the Apc gene leads to nuclear accumulation
of β-catenin and over expression of cyclin D1 and in-
creased Cdk4 activity [8,10]. We have shown that cyclin
D1, and Cdk4 expression is markedly reduced in mature
epithelium at the luminal surface but clearly present
within adenomas. Modulation of these proteins may pro-
vide effective chemoprevention against colorectal cancer.
Normally the intestine is covered by a mucosal layer that
is composed of crypts deep in the mucosa and villi
(small intestine) or the intercrypt table (large intestine)
at the luminal surface [24]. Epithelial stem cells are lo-
cated near the base of the crypts [25,26]. Epithelial cells
undergo proliferation and differentiation as they migrate
up the crypt wall towards the lumen [27]. Mutations that
occur in stem cells allow for persistence and accumula-
tion of the mutations through stem cell self-renewal.
Therefore, mutations in the stem cells pass to the future
generations of stem cells and progeny daughter cells.
Apc mutant mice develop large numbers of adenomas
in their small intestine and fewer in the large intestine
whereas; FAP patients develop low numbers of aden-
omas in their small intestine and large numbers of aden-
omas in their large intestine. In spite of differences in
localization of adenomas, it has been widely used as a
predictive model for human colorectal cancer [28-30].
In our study, we first used a genetic approach to explore
the role of Cdk4 in reducing intestinal tumors in Apc−/+
mice. The results of this study revealed that the disruption
of Cdk4 activity in Apc−/+ mice led to a significantly re-
duced number and size of tumors. We found that Apc−/+
Cdk4−/− mice had fewer tumors of all sizes that are less
than 3 mm in diameter compared to Apc−/+ Cdk4+/+ mice.
This demonstrates that the Cdk4 pathway is important in
the development or maintenance of adenomas in Apc−/+
mice. Since the smallest microadenomas were reduced in
number, Cdk4 may affect initiation or very early events of
microadenoma formation in mice heterozygous for Apc.
Thus, earliest microadenomas were reduced in number
due to reduced Cdk4 activity. The loss of Cdk4 leads to
hypophosphorylation of Rb and decreased tumorigenesis.
Several studies have demonstrated the contribution of
Cdk4 in tumor development in brain, skin, pancreas, eye,
and tooth [31-33]. We conclude that Cdk4 is a potentialtarget for blockade in the chemoprevention of colorectal
cancer.
In our in vitro studies, the effects of silibinin on
growth inhibition of intestinal tumors was demonstrated.
We also observed an associated effect of silibinin on Rb
phosphorylation and cyclin D1 levels in HT-29 cell lines
and in vivo in intestinal tissue. It is possible that silibinin
directly reduces Cdk4 activity in addition to loss of it’s
binding partner cyclin D1 that leads to hypophos-
phorylation of Rb. These results suggest that silibinin
may cause cell cycle arrest at the G0 to G1 stages of the
cell cycle due in part to its targeting of the Cdk4 signal-
ing pathway (Cdk4, cyclin D1, pRb) at multiple steps.
The silibinin effects included significant alterations in
cell cycle regulator proteins causing cell cycle arrest
followed by cell growth inhibition and apoptotic cell
death. Other studies have shown that G1 arrest was re-
lated to strong induction of Cip1/p21 and Kip1/p27 pro-
tein levels and a significant decrease in Cdk2, Cdk4 and
their associated cyclin E and cyclin D1 protein levels fol-
lowing HT-29 treatment with silibinin [34]. Apc−/+ mice
are a widely accepted preclinical model to evaluate the
antitumor efficacy of candidate chemopreventive agents
for colorectal cancer and to determine associated tox-
icity [35]. In this study examination of the very early
stages of colorectal neoplasia (formation of small mic-
roadenomas) was assessed in vivo. Dietary supplementa-
tion with silibinin (0.2%) resulted in a decrease in
activity of the Cdk4 pathway and markedly reduced ad-
enoma formation in Apc−/+ mice. The smallest tumors
(< 1 mm) were decreased in number suggesting that
silibinin may have inhibited microadenomas at or shortly
after they were initiated as well as inhibiting adenoma
growth. Other studies have show that in the colon,
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errant crypt foci in azoxymethane (AOM) treated rats
and induced GST and NQO1 [36]. Sangeetha et al. and
Gershbein et al. found that dietary feeding of silymarin
significantly inhibited development of intestinal adeno-
carcinomas in DMH treated rats [37,38]. In addition,
Rajamanickam at al. showed that silibinin significantly
inhibited adenoma formation in Apc mutant mice by
inhibiting cell proliferation [39]. However, no studies
have explored mechanistically the antiproliferative activ-
ity of silibinin on the Cdk4 pathway in Apc mutant mice.
Our in vivo results show that silibinin can significantly
inhibit cell proliferation in the crypts and adenomas in
the intestine in Apc−/+ mice as evidenced by Ki67 stain-
ing. Cell proliferation depends on a tightly regulated sys-
tem involving multiple genes, many of which have been
implicated in multistep carcinogenesis. This is consistent
with many studies that have suggested that silibinin in-
duces growth inhibition and promotes cell cycle arrest
in many CRC cell lines [17,34,40,41]. Increased TUNEL-
positive cells were noted within the crypts in the normal,
nonpolypoid mucosa in mice that received silibinin as
well as in adenomas. It was previously shown that
silibinin causes apoptotic cell death in SW480 and
SW620 cells [41,42]. Many studies have shown that
elimination of transformed cells via apoptosis in the
colon is an important step to restore normal epithelial
growth [42,43]. Alterations in apoptosis also have pro-
found effects on the progression of benign to malignant
tumors [44,45]. In summary, disruption of the homeo-
static balance between proliferation and apoptosis has
been broadly implicated in cancer and silibinin tips the
balance away from development of colorectal cancer.
Rajamanickam et al. have suggested that silibinin has
multiple mechanisms potentially driving its anticancer
effects in Apc−/+ mice. These effects include apoptosis,
decreasing beta-catenin levels and transcriptional activ-
ity, and modulating the expression profile of cytokines
[39]. Also, silibinin inhibits PP2A/AKT/mTOR pathways
and targets the inflammatory NF-kB pathways sup-
presses colorectal cancer stem like cells [46,47]. In the
present study, silibinin has inhibitory effects on the Cdk4
pathway and appears to mediate at least some of its effects
through the cell cycle, proliferation of adenomas, and
apoptosis (Figure 9). The relative importance of each
Cdk4 pathway target for silibinin activity in altering intes-
tinal epithelial cells remains to be fully elucidated.
Conclusions
In conclusion, results described in this report suggest
that the inhibition of the Cdk4 pathway as evidenced by
hypophosphorylation of Rb protein contributes to the
antitumor activity of silibinin and the chemopreventive
ability of silibinin is likely related in part to itssuppression of cell proliferation or augmentation of
apoptosis of mutated intestinal epithelial cells. There-
fore, silibinin may serve as a non-toxic chemopreventive
agent for colon cancer and it clearly deserves further
consideration for colorectal cancer prevention studies.
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